New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). (Q37437435)

20 August 2017

1 reference

title

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

20 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

Rafeeq Ali

1

1 reference

PubMed ID

19353360

20 August 2017

Kenneth Cusi

series ordinal

2

1 reference

PubMed ID

19353360

20 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

41

1 reference

20 August 2017

4

1 reference

20 August 2017

265-278

1 reference

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

20 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Silent non-alcoholic fatty liver disease-a clinical-histological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Cryptogenic cirrhosis and NAFLD: are they related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Cytokines and the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

NASH: a mitochondrial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The ins and outs of mitochondrial dysfunction in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Adiponectin and its receptors in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Peroxisome Proliferator-Activated Receptors and the Control of Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Non-alcoholic steatohepatitis in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Hepatic effects of dietary weight loss in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Long-term mortality after gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Benefits of lifestyle modification in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effect of weight reduction on hepatic abnormalities in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effect of weight control on hepatic abnormalities in obese patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Dietary fat content modifies liver fat in overweight nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Orlistat in the treatment of NASH: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

Nonalcoholic Fatty Liver Disease in Severely Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802552437

10.1080/07853890802552437

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19353360